Skip to main content

Distribution and Supply Chain Models in the Cell & Gene Therapy Landscape

How are Cell and Gene therapies transforming patients' lives? What is their impact on the current and future curative treatment landscape? How should pharma manufacturing and other relevant stakeholders plan for a higher degree of operating model sophistication required for Cell and Gene therapies?

Cell and Gene therapies (CGT), including personalized medicines, have rapidly transformed the curative treatment landscape. The personalized nature of these therapies demand a greater degree of operating model sophistication. The complexity stems from a requirement for an end-to-end traceability of viable cells to manufacturing to bedside infusion, and long term follow-up. Further, the need to provide a greater degree of transparency of manufacturing processes to patients and healthcare professionals, including regulatory requirements, makes it critical to think through innovative operating model designs.

What is the focus of the Distributor Paper?In this paper, we will focus on the Cell and Gene therapy product flow, outline the hurdles and opportunities created within supply chain distribution flows, describe alternate distribution models expected in the CGT supply chain and explore the required capabilities.

The paper aims to answer questions such as:

  • What are the primary drivers facilitating the CGT operating model?
  • What differentiates CGT from traditional distribution models?
  • How will CGT change the way biopharma companies collaborate with logistic partners?
  • How do biopharma companies partner with distribution firms?
  • How are distributors innovating beyond their traditional role?

Did you find this useful?

Thanks for your feedback

If you would like to help improve further, please complete a 3-minute survey